Dataset Information

A novel method to isolate mesenchymal stem cells from mouse umbilical cord.

ABSTRACT: Mesenchymal stem cells (MSCs), derived from various tissues, are considered an ideal cell source for clinical use, among which MSCs from the umbilical cord exhibit advantages over those from adult tissues. In preclinical studies, mouse models and xenogeneic MSC treatment are most commonly used to imitate diseases and clinical practice, respectively. However, the efficiency of cross?species therapy remains controversial, making it difficult to elucidate the underlying mechanisms. Thus, allogeneic therapy may be more instructive and meaningful in clinical use. To confirm this hypothesis, the present study established a novel method for the isolation and expansion of MSCs from mouse umbilical cords (mUC?MSCs) to support in vivo experiments in mice. MSCs were isolated from mUCs and mouse bone marrow (mBM), and then identified by flow cytometry. The differences in mUC?MSCs and mBM?MSCs were analyzed using a growth curve and their differentiation ability. The results showed that the harvested cells exhibited general characteristics of MSCs and possessed the capacity for long?term culture. Despite having similar morphology and surface antigens to MSCs derived from mouse bone marrow, the mUC?MSCs showed differences in purification, proliferation, stem cell markers and differentiation. In addition to detailed characterization, the present study verified the presence of Toll?like receptor 3 (TLR3), an important component of immune responses, in mUC?MSCs. It was found that the activation of TLR3 upregulated the levels of stemness?related proteins, and enhanced the secretion and mRNA levels of inflammatory cytokines in the pre?treated mUC?MSCs. Collectively, the results of the present study provide further insight into the features of newly established mUC?MSCs, providing novel evidence for the selection of murine MSCs and their responses to TLR3 priming.

SUBMITTER: Zhang B

PROVIDER: S-EPMC5780165 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

A novel method to isolate mesenchymal stem cells from mouse umbilical cord.

Zhang Bin B Zhang Jie J Shi Hui H Mao Fei F Wang Juanjuan J Yan Yongmin Y Zhang Xu X Qian Hui H Xu Wenrong W

Molecular medicine reports 20171103 1

Mesenchymal stem cells (MSCs), derived from various tissues, are considered an ideal cell source for clinical use, among which MSCs from the umbilical cord exhibit advantages over those from adult tissues. In preclinical studies, mouse models and xenogeneic MSC treatment are most commonly used to imitate diseases and clinical practice, respectively. However, the efficiency of cross‑species therapy remains controversial, making it difficult to elucidate the underlying mechanisms. Thus, allogeneic ...[more]

PMID: 29115623

Similar Datasets

Project description:BackgroundAutism is a pervasive neurodevelopmental disorder. At present there are no defined mechanisms of pathogenesis and therapy is mostly limited to behavioral interventions. Stem cell transplantation may offer a unique treatment strategy for autism due to immune and neural dysregulation observed in this disease. This non-randomized, open-label, single center phase I/II trial investigated the safety and efficacy of combined transplantation of human cord blood mononuclear cells (CBMNCs) and umbilical cord-derived mesenchymal stem cells (UCMSCs) in treating children with autism.Methods37 subjects diagnosed with autism were enrolled into this study and divided into three groups: CBMNC group (14 subjects, received CBMNC transplantation and rehabilitation therapy), Combination group (9 subjects, received both CBMNC and UCMSC transplantation and rehabilitation therapy), and Control group (14 subjects, received only rehabilitation therapy). Transplantations included four stem cell infusions through intravenous and intrathecal injections once a week. Treatment safety was evaluated with laboratory examinations and clinical assessment of adverse effects. The Childhood Autism Rating Scale (CARS), Clinical Global Impression (CGI) scale and Aberrant Behavior Checklist (ABC) were adopted to assess the therapeutic efficacy at baseline (pre-treatment) and following treatment.ResultsThere were no significant safety issues related to the treatment and no observed severe adverse effects. Statistically significant differences were shown on CARS, ABC scores and CGI evaluation in the two treatment groups compared to the control at 24 weeks post-treatment (p < 0.05).ConclusionsTransplantation of CBMNCs demonstrated efficacy compared to the control group; however, the combination of CBMNCs and UCMSCs showed larger therapeutic effects than the CBMNC transplantation alone. There were no safety issues noted during infusion and the whole monitoring period.Trial registrationClinicalTrials.gov: NCT01343511, Title "Safety and Efficacy of Stem Cell Therapy in Patients with Autism".

Dataset Information

A novel method to isolate mesenchymal stem cells from mouse umbilical cord.

Publications

A novel method to isolate mesenchymal stem cells from mouse umbilical cord.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets